Zacks Investment Research on MSN

Sage Group (SGPYY) upgraded to strong buy: Here's why

Sage Group PLC (SGPYY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This ...
Nasdaq

Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for

Wall Street expects a year-over-year decline in earnings on lower revenues when Sage Therapeutics, Inc. (SAGE) reports results for the quarter ended December 2024. While this widely-known consensus ...
Business Insider

SAGE Therapeutics, Inc. Q4 Loss decreases, beats estimates

(RTTNews) - SAGE Therapeutics, Inc. (SAGE) released Loss for fourth quarter that decreased from last year and beat the Street estimates. The company's bottom line totaled -$32.71 million, or -$0.55 ...
Houston Chronicle

Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Misses Revenue Estimates

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $2.12 per share versus the Zacks Consensus Estimate of a loss of $2.16. This compares to loss of $2.47 per share a year ago. These ...
Nasdaq

Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for

Sage Therapeutics, Inc. (SAGE) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2023. This widely-known consensus ...